At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 531 enrolled
Drug / intervention
telmisartan+amlodipine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Filtered Trial for Amlodipine Non-responder
In Brief
A Phase 3 clinical trial evaluating telmisartan+amlodipine and amlodipine for Hypertension. Completed, enrolled 531 participants across 41 sites.
Detailed Summary
To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedNov 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedNov 14, 2007
Enrollment StartOct 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.6 years ago
Interventions
telmisartan+amlodipinedrug
amlodipinedrug